Clinical Trial Update: Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Nilotinib in patients with advanced gastrointestinal stromal tumor has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Gastrointestinal Stromal Tumor | Phase 2 | Status: COMPLETED